Cryoglobulinemic Vasculitis After Hepatitis C Is Cured

Table of Contents

1. What Cure Means in These Studies
2. Vasculitis Symptoms After the Virus Clears
3. Response by Organ: Skin, Joints and Nerves
4. Whether Kidney Disease Recovers
5. Cryoglobulins That Stay in the Blood
6. Relapse Rates and Timing
7. What Predicts Persistence or Relapse
8. B-Cell Clones and Lymphoma After Cure
9. Rituximab After Antiviral Cure
10. Older Interferon-Based Cure for Comparison
11. Follow-Up Measures the Studies Used
12. What Is Not Known
13. Key Research Papers
14. Connections
15. Featured Videos

What Cure Means in These Studies

In hepatitis C research, cure has a precise meaning: a sustained virologic response, which is no detectable virus in the blood 12 weeks after treatment ends. Direct-acting antivirals are the tablets that produce it. In people with cryoglobulinemic vasculitis the virologic results are close to those in other patients: 99.8% of 913 patients in one international cohort (Fayed 2022), 97.2% of 148 in another (Cacoub 2019), and 297 of 313 (95%) in a 2018 pooled review (Rutledge 2018).

Cure of the virus and recovery from the vasculitis are separate events, and the two can part company. A hepatitis C virus infection drives a group of B cells to make the abnormal antibody. Once the virus is gone, that stimulus stops, but three things can outlast it: the cryoglobulins already being made, the B-cell clones that make them, and damage already done to nerves and kidneys. Each one is measured separately in the studies below.

Studies define a good result differently, which explains much of the spread in their figures. A complete response meant improvement in every affected organ in one French cohort (Cacoub 2019). In the Italian cohort it was split further, and only a "full complete response" meant every symptom had disappeared (Kondili 2022). A Barcelona study used a Birmingham Vasculitis Activity Score of 0, a standard symptom score, or improvement in all affected organs (Bonacci 2017).

Back to Table of Contents

Vasculitis Symptoms After the Virus Clears

The measured benefit of cure is large. A meta-analysis of observational data found that complete remission of vasculitis was far more common in people who cleared the virus than in those who did not (odds ratio 20.76, 95% confidence interval 6.73 to 64.05). The authors noted that there are no randomized comparisons of cure against no cure for this question (Cacoub 2018).

Results from individual cohorts and reviews:

• Across 18 observational studies, among people cured at 12 weeks, the pooled complete clinical response was 64.8% and the partial response 23.8% (Boonpheng 2026).
• A systematic review of 19 studies found complete clinical response in 63.7% to 90.2% of cured patients (Danishwar 2022).
• 148 patients, median follow-up 15.3 months: complete response 72.6%, partial 22.6%, none 4.8%, and 4 deaths (2.8%) (Cacoub 2019).
• 41 patients given sofosbuvir plus daclatasvir: complete response in 37 (90.2%), after a median of 12 weeks of therapy (Saadoun 2017).
• 44 Italian patients, all cured: the mean Birmingham Vasculitis Activity Score fell from 5.41 to 1.27 at 24 weeks after treatment. Every patient had some clinical response (Gragnani 2016).
• 22 patients in a single centre, all cured: 63.7% met a combined definition of clinical and immune response at 12 weeks, and 36.3% met part of it (Lauletta 2017).
• A tertiary care centre, 18 people with symptoms, including 10 with severe or life-threatening vasculitis: at 12 weeks after treatment, 38.8% had a complete and 22.2% a partial clinical response. The authors read this as a possible delay in response, particularly in severe disease (Emery 2017).

How Fast Improvement Comes

Response can start while treatment is still running. In the 24-week VASCUVALDIC trial of sofosbuvir plus ribavirin, 21 of 24 patients reached complete clinical response by week 24: 25% at week 4, 16.6% at week 8, 29.2% at week 12, 12.5% at week 16 and 4.2% at week 20. Only 74% of those patients went on to a sustained virologic response, so a response on treatment did not guarantee cure (Saadoun 2016). In the Italian national cohort of 423 cured patients, improvement rose over time and reached 76% at month 12 after treatment (Kondili 2022).

Blood studies help explain the change. In 27 patients in Paris, the abnormal memory B cells linked to this disease fell from 35.7% to 14.9% of the measured population after direct-acting antivirals, while regulatory T cells, which restrain immune attack, rose from 1.5% to 2.1% (Comarmond 2017).

Treatment-Sparing Effect

In Barcelona, 13 patients with vasculitis were on immune-suppressing drugs at the start. After antiviral therapy these were reduced in 4 and stopped in 6 (Bonacci 2017). A 2018 review reported that fewer than 5% of patients treated with interferon-free regimens needed immunosuppression, while those with severe vasculitis appeared still to need it (Rutledge 2018).

Back to Table of Contents

Response by Organ: Skin, Joints and Nerves

Organs recover at different rates. Skin responds best and nerves worst. The clearest single set of figures comes from 148 patients followed for a median of 15.3 months (Cacoub 2019):

• Purpura (skin spots) cleared in 97.2%.
• Kidney involvement cleared in 91.5%.
• Joint pain cleared in 85.7%.
• Nerve disease cleared in 77.1%.

Those are among the better figures in the literature. Other groups measured less complete recovery, and the kidney figure in particular is much lower in studies built around kidney disease (see the next section).

Skin

An Egyptian cohort of 63 patients given sofosbuvir plus daclatasvir reported improvement of purpura in 62 (98.4%), against 71.42% for glomerulonephritis (Hassan 2018). A tertiary care centre also found skin the most likely feature to resolve completely, with a 39% reduction, against 11.2% for kidney and 11.1% for nerve symptoms (Emery 2017). In a small Italian series, purpura regressed lastingly in 8 of 12 patients and joint pain in 9 of 12 at 48 weeks (Mazzaro 2018).

Joints and Fatigue

Early improvement does not always hold for these symptoms. In the full text of the Italian cohort, the symptoms that most often persisted 2 years after the virus cleared were joint pain (45%), fatigue (41%), nerve symptoms (38%) and dry eyes and mouth (37%) (Kondili 2022).

Nerves

Nerve disease stands out in several studies as the slowest and least complete feature:

• People with peripheral neuropathy were less likely to have a full response (odds ratio 0.31) (Cacoub 2019).
• Neuropathy was independently linked to a lower chance of a full complete response (Kondili 2022).
• Neuropathy still present at the end of antiviral treatment was an independent risk factor for later relapse (Fayed 2022).
• In a Hungarian cohort followed for a median of 5 years, polyneuropathy "did not show improvement by any means" (Elthes 2025).
• In the small Italian series, neuropathy improved in 7 of 10 patients (Mazzaro 2018).

One study measured nerves directly, using nerve conduction tests before and about 10 months after treatment in 94 people with hepatitis C. This group was not limited to people with vasculitis. Of 22 with abnormal tests at the start, 4 had normal tests afterward and 3 had died or developed liver cancer. Depressed reflexes fell from 34% to 12%, and neuropathic pain from 39% to 11%. Cryoglobulins showed no link to neuropathy at the start in this group (Zanone 2021).

Back to Table of Contents

Whether Kidney Disease Recovers

Kidney disease often improves after cure, but full recovery is the minority result in series that focused on it. Cryoglobulinemic kidney disease usually appears as membranoproliferative glomerulonephritis.

• 52 patients with glomerulonephritis in a 2018 pooled review: 94% cured, 33% in full remission, 29% in partial remission, and no reports of worsening kidney function (Rutledge 2018).
• 67 patients in a 2019 review: 92.5% cured, and 68.5% in full or partial remission. In all, 43% also took immunosuppressive drugs while on antivirals. A few cases of new or relapsing glomerular disease after cure were recorded (Fabrizi 2019).
• 104 patients in a 2025 narrative review: complete response in 29%, partial in 42%. The authors describe this as still a difficult-to-treat disease (Fabrizi 2025).
• 7 patients in one series: those with glomerulonephritis who were cured had lower creatinine and less protein in the urine, including people not on immunosuppression (Sise 2016).
• 2 detailed cases: both reached only partial remission and stayed dependent on immunosuppression for more than 6 months after a cure. The authors state that the kidney response can lag behind the virologic response (Abdelhamid 2022).

Long-Term Kidney Outcomes

The RENALCRYOGLOBULINEMIC study followed 139 Spanish patients for a median of 138 months: 100 treated with direct-acting antivirals, 24 with interferon and ribavirin, and 15 untreated. Direct-acting antiviral treatment was tied to better kidney survival (hazard ratio 0.10) and lower overall mortality (hazard ratio 0.12). A hazard ratio below 1 means lower risk. Treatment was not randomized (Pérez de José 2021).

Kidney filtering measurements give a less simple picture. In a 10-year Taiwanese cohort of 1,212 people with hepatitis C, not all with cryoglobulinemia, estimated filtering rate was lower 24 weeks after treatment in those cured, whatever the regimen. It returned to baseline after interferon but remained lower for up to 4 years after direct-acting antivirals. Mixed cryoglobulinemia modified this: the combination of direct-acting antiviral treatment and mixed cryoglobulinemia was positively associated with filtering rate (Chang 2024).

Poor Starting Kidney Function

Poor kidney function before treatment predicted a weaker response in two different eras. In the interferon era, a glomerular filtration rate of 70 ml/minute or lower reduced the odds of complete clinical response (odds ratio 0.18) (Saadoun 2006). In the direct-acting antiviral era, kidney involvement was tied to no clinical response (Kondili 2022) and independently to later relapse (Fayed 2022). At relapse, kidney involvement was present in 85.2% of patients (Fayed 2022).

Kidney Disease First Seen After Cure

Cryoglobulinemic kidney disease has been reported in people who had a successful cure. In an Egyptian cohort of 12,985 treated patients, 50 who were referred with abnormal kidney tests or protein in the urine after cure had detectable cryoglobulins described as new. Membranoproliferative glomerulonephritis was the most common biopsy finding (52%), and chronic kidney disease developed in 46%. The authors call this a rare complication (Fayed 2018). A separate case report describes vasculitis with kidney involvement 3 years after cure with interferon (Gaudêncio 2021).

The international kidney guideline group Kidney Disease: Improving Global Outcomes covers kidney diseases associated with hepatitis C in its 2022 guideline (Martin 2022).

Back to Table of Contents

Cryoglobulins That Stay in the Blood

Cryoglobulins often stay detectable after cure, and for some people they remain for years. Reported figures differ with how long after treatment the test is done.

• At 12 weeks after treatment, the pooled rate of complete immune response was 43.9% (Boonpheng 2026).
• At 12 weeks in Barcelona, 48% had a complete immune response, and activation markers persisted in 52% (Bonacci 2017).
• At week 36, half of 41 Paris patients had no detectable cryoglobulin. The mean level had fallen from 0.56 to 0.21 g/L (Saadoun 2017).
• In the 148-patient cohort, cryoglobulins were no longer detected in 53.1% (Cacoub 2019).
• At more than 12 months, cryoglobulins remained detectable in 42% of 45 Rome patients (Visentini 2019).
• At 96 weeks, despite viral clearance and regression of vasculitis, cryoglobulins persisted in 12 patients (21%) in an Italian study (Lauletta 2024).
• At a median of 24 months in Barcelona, 20% of patients were still positive. The study reported reductions in cryocrit, the proportion of the blood sample made up of cryoglobulin, from 2.6% to 0% (Bonacci 2018).

The type of cryoglobulin matters. In a Hungarian cohort tested yearly, cryoglobulins took a median of 36 months to disappear in type II disease and 12 months in type III, and symptoms improved in parallel. Those authors state that monitoring remains important after cure, especially for type II (Elthes 2025). A Taiwanese cohort of 891 cured patients found mixed cryoglobulinemia in 29.7% at 24 weeks after therapy (Chang 2025).

What Persistence Means

A positive test after cure does not by itself mean active vasculitis. Cryoglobulins persisted despite regression of vasculitis in one study (Lauletta 2024). In another, 78% had a complete clinical response while cryoglobulins stayed detectable in 42% for more than 12 months (Visentini 2019). In Barcelona, people with cryoglobulins but no symptoms before treatment responded immunologically about as often as those with vasculitis, at 70% and 66% (Bonacci 2018).

A rising level does have clinical meaning in reports of relapse. In 8 patients who relapsed after an interferon-based cure, cryoglobulin rose from 0.08 g/L at the end of treatment to 0.3 g/L at relapse, and the C4 complement level fell (Landau 2008). Among people who began treatment without cryoglobulins, a Mongolian study found 8 of the 118 tested positive at 3 months, linked to cirrhosis and to cancers in other organs. The paper gives both 4.6% and 6.7% for this group (Dashjamts 2024).

Whether Hidden Virus Explains It

Testing has mostly found no virus behind persistent disease. In the 2008 relapse series, tests were negative in the serum and the cryoprecipitate of all 7 patients tested, and no viral replication was found in the blood cells of the 6 tested (Landau 2008). Testing was also negative in blood cells in 2 cases with kidney disease (Abdelhamid 2022). One case report differs: virus was undetectable in the serum but detectable in the cryoprecipitate after sofosbuvir and ribavirin (Chowdhury 2017).

Back to Table of Contents

Relapse Rates and Timing

Relapse is well documented in people whose virus stays gone. Reported rates mostly range from 4% to 18% (Danishwar 2022). Timing data are newer. In the largest cohort, risk was low in the first year and rose in the second.

• Largest cohort: cumulative relapse was 0.7% at 12 months, 12.3% at 24 months and 13.1% at 36 months after treatment. Egypt, France and Italy contributed patients; the study was retrospective (Fayed 2022).
• Italian national cohort: among 137 patients with a full complete response and available follow-up, 18 (13%) relapsed, and the relapse was transient in 66.7% (Kondili 2022).
• Rome: 18% of 70 cured with direct-acting antivirals relapsed over about 30.5 months of follow-up (Colantuono 2021).
• Barcelona: 5 of 46 patients with vasculitis (11%) relapsed within 2 years. Four of the 5 had cirrhosis. The relapses included severe organ damage and death (Bonacci 2018).
• Hungary: 2 relapses of cryoglobulinemia and related symptoms among 40 patients over a median of 5 years (Elthes 2025).
• Paris: no relapses among 41 patients over a median of 26 months (Saadoun 2017).

Fluctuation Short of Relapse

The Italian cohort also counted any deterioration of an earlier response. Of the 423 cured patients, 373 (88%) responded at some point, and 49.6% had some deterioration, at a median of 19 months. The share with no deterioration was 58% at 12 months and 41% at 24 months. The authors state that eradicating the virus "may not correspond to a persistent clinical improvement" (Kondili 2022).

What Relapse Looks Like

Relapse was not always mild. In the largest cohort, skin involvement was present in all 115 relapses, kidney involvement in 85.2% and peripheral neuropathy in 81.7%. Glucocorticoids were used in 90.9%, along with plasma exchange in 50%, cyclophosphamide in 37.3% and rituximab in 6.4%. Eleven of those who relapsed died, mainly from infections. The authors describe relapses as moderate to severe and as affecting survival after 24 months (Fayed 2022).

An older interferon-era series looks different: 8 relapses appeared a mean of 2.5 months after treatment, mainly as purpura and joint pain, and most were brief. The authors suggested that stopping interferon might be the trigger. In 3 of the 8, however, symptoms persisted, and 2 of those 3 were found to have B-cell lymphoma (Landau 2008).

Isolated case reports extend the time range further. A 57-year-old man developed vasculitis with kidney involvement 3 years after cure (Gaudêncio 2021), and a four-patient series from 2005 describes persistent vasculitis after successful treatment (Levine 2005).

Back to Table of Contents

What Predicts Persistence or Relapse

Several factors have been linked to a worse course. Most come from one or two observational studies, and no paper read for this page validated a scoring system.

Clinical Features

• Male sex, skin ulcers, kidney involvement at the start and peripheral neuropathy at the end of treatment independently predicted relapse (Fayed 2022).
• Older age and kidney involvement were tied to no clinical response. Older age, neuropathy and high cryocrit were tied to a lower chance of full complete response (Kondili 2022).
• A severe form of vasculitis (odds ratio 0.33) and peripheral neuropathy (odds ratio 0.31) lowered the odds of a full response (Cacoub 2019).
• Cirrhosis was present in 4 of 5 relapsing patients (Bonacci 2018). A five-patient case series also proposed that people with cirrhosis have a reduced ability to clear immune complexes (Cornella 2015).

Blood Tests

• High rheumatoid factor before treatment was tied to deterioration or relapse (Kondili 2022).
• Low starting cryocrit (below 2.7%) was the only factor linked to complete immune response at 12 weeks (odds ratio 9.8) (Bonacci 2017).

Clonal and Genetic Markers

The most direct evidence compares 98 cured Florence patients: 52 with a complete clinical response and 46 with symptoms that stayed or returned. Those with lasting symptoms more often had monoclonal B-cell lymphocytosis (a small circulating clone without lymphoma), at 17% against 4%. They also more often had the t(14;18) chromosome change (40% against 17%) and abnormal free light chain ratios (47% against 17%). At least one marker was abnormal in 70% against 29%. Where samples existed from before treatment, at least one marker was present in 79% against 43%, which suggests that these results may foreshadow the outcome. A variant of the notch4 gene was also more common in the persisting group (Gragnani 2021).

A systematic review adds further gene variants linked to persistence and recurrence, in IFNL3, ARNTL, RETN and SERPINE1, with a call for validation in larger multicentre studies (Danishwar 2022).

Back to Table of Contents

B-Cell Clones and Lymphoma After Cure

A clone is a family of identical B cells. In cryoglobulinemia, clones make the antibody that forms the cryoglobulin. Several studies now show that curing the virus often leaves the clone in place.

• 67 patients: among those with a clone in the blood, only 22% became negative. The study included 30% with monoclonal B-cell lymphocytosis and 6 with overt lymphoma, and 20% carried a change in the MYD88 gene. The authors state that direct-acting antivirals do not eliminate the clonal changes in a large proportion of cases (Pozzato 2020).
• 23 patients with lymphoproliferative disease or monoclonal lymphocytosis: vasculitis responded completely, yet clones found in 19 at the start were still present in 17 (Mazzaro 2023).
• 45 cured patients: clones detected in 18 and persisting in 17 of them through a median of 18.5 months. Nine of those 17 had cleared their cryoglobulins and had a complete vasculitis response. Two of these later relapsed. The authors call the cells "dormant" and propose that events disturbing B-cell balance can reactivate them (Visentini 2019).
• A systematic review: clones persisted in 31% to 40% of patients (Danishwar 2022).

The interferon comparison matters here. In a retrospective Rome study, people cured with direct-acting antivirals reduced circulating clones less efficiently than those cured with interferon (Colantuono 2021). See the interferon section for the limits of that comparison.

Lymphoma and Monoclonal Disease Found After Cure

Persisting symptoms can have another cause. Reports describe the following:

• In a 2008 series, B-cell lymphoma was diagnosed in 2 of the 3 patients whose vasculitis symptoms persisted after cure. The authors raise a different underlying condition, especially B-cell lymphoma, as an explanation for persistent symptoms (Landau 2008).
• In a Hungarian cohort of 40 patients, 2 had lymphoma at the time of diagnosis. One resolved without chemotherapy during follow-up, and one aggressive lymphoma needed combination chemotherapy. The authors state that long-term complications, including lymphoma, may still occur after cure (Elthes 2025).
• A 72-year-old woman, cured with interferon, later developed cryoglobulinemic glomerulonephritis together with monoclonal gammopathy of undetermined significance (Ishitoku 2023).
• A man with cured hepatitis C and kidney disease developed a persistent monoclonal immunoglobulin M protein. No lymphoma or myeloma appeared on repeated bone marrow tests and a positron emission tomography scan (Pelletier 2019).

Lymphoma Already Present When Antivirals Start

Results for existing lymphoma are mixed. In one series, 46 patients with indolent B-cell lymphoma or chronic lymphocytic leukemia received direct-acting antivirals, and 45 were cured. The lymphoma responded in 67% overall, including 26% with a complete response and 73% among those with marginal zone lymphoma. Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma had no response. Median follow-up was 8 months (Arcaini 2016). Smaller cryoglobulinemia series saw less:

• One complete response among 6 patients with lymphoma, with no change in the lymph nodes of the other 5 (Pozzato 2020).
• No hematologic response in 2 people with marginal zone lymphoma (Mazzaro 2018).
• Partial vasculitis response and no significant fall in the clone in 2 people with indolent lymphoma (Gragnani 2016).
• One small lymphocytic lymphoma that progressed despite viral clearance (Lauletta 2017).

Two later reviews state that the benefit of direct-acting antivirals in B-cell lymphoma needs confirmation in larger studies with longer follow-up (Cacoub 2022; Mazzaro 2026).

Back to Table of Contents

Rituximab After Antiviral Cure

Rituximab is an antibody that removes B cells, which makes it a logical treatment when a clone continues after the virus has gone. The evidence for that exact situation is thin. The searches for this page found no randomized trial of rituximab given for vasculitis that persists or returns after a cure with direct-acting antivirals. A 2018 Cochrane review included 10 randomized or quasi-randomized studies, and none of them evaluated direct-acting antivirals (Montero 2018).

What Has Been Reported After Cure

• Among 115 relapses after cure, rituximab was used with glucocorticoids in 6.4% (Fayed 2022).
• In a Rome comparison, people cured with direct-acting antivirals more often needed rituximab than those cured with interferon (Colantuono 2021).
• In one case report, rituximab first lowered creatinine from 2.43 to 1.51 mg/dl and urine protein ratio from 7.8 to 0.4 g/g. Later courses gave only brief benefit, and the kidney disease stayed dependent on long-term plasma exchange (Pelletier 2019).
• Two people given rituximab before antiviral therapy did not clear cryoglobulins more effectively (Cornella 2015).

Evidence From Before or Without Cure

Most rituximab data come from patients who had not been cured:

• The main randomized trial enrolled 59 patients. Hepatitis C patients entered only when antivirals had failed or were not indicated. At 12 months, 64.3% on rituximab stayed on their first treatment against 3.5% on conventional treatment, and median response lasted 18 months. The trial gave two 1 g infusions (De Vita 2012).
• A low-dose trial in 52 patients gave 250 mg/m² twice. Response at 3 months was 81%, and relapse occurred in 41%, at a median of 6 months. These figures were not significantly different from those in published high-dose studies (Visentini 2015).
• Repeated low-dose treatment in 37 refractory patients, 34 of them with hepatitis C: 81% responded and 22 relapsed after a mean of 15.7 months. Retreatment brought response in 91%, 80% and 100% at successive relapses. Severe reactions occurred in 3 patients (Colantuono 2017).
• In the interferon era, adding rituximab to peginterferon and ribavirin gave faster remission, better complete kidney response (80.9% against 40%) and more cryoglobulin clearance (68.4% against 43.6%) in a non-randomized comparison of 93 patients (Saadoun 2010).
• The Cochrane review found that rituximab may slightly improve skin vasculitis and makes little or no difference to kidney disease, with an uncertain effect on cryocrit (Montero 2018).
• A 2023 review of 9 studies reported consistent benefit, mild adverse events in general and rare severe reactions (Covic 2023).

Expert Panels

The Italian Study Group of Cryoglobulinemia issued 17 recommendations on rituximab in 2023, after a systematic review of 27 studies (Quartuccio 2023). An earlier panel of the same group recommended rituximab-based treatment for skin ulcers, peripheral neuropathy or glomerulonephritis, and for life-threatening disease persisting after plasma exchange. It stated that the treatment approaches for severe disease rest largely on anecdotal data (Galli 2019).

Boxed Warnings and Disease-Specific Reactions

The US labels for rituximab products carry a boxed warning, the strongest warning the Food and Drug Administration requires, for four hazards:

• Fatal infusion-related reactions. Deaths within 24 hours of infusion have occurred. About 80% of fatal reactions occurred with the first infusion.
• Severe mucocutaneous reactions of the skin and mouth, including fatal ones.
• Hepatitis B virus reactivation, in some cases causing fulminant hepatitis, liver failure and death. The label calls for screening all patients before treatment and monitoring during and after it.
• Progressive multifocal leukoencephalopathy, a brain infection, including fatal cases.

Labels for hepatitis C direct-acting antivirals also carry a boxed warning for hepatitis B reactivation in people with both infections, some cases resulting in fulminant hepatitis, liver failure and death.

One further hazard is specific to this disease. Among 22 people with hepatitis C vasculitis given rituximab, 6 (27.3%) had systemic reactions: 4 had a severe vasculitis flare within 1 or 2 days, and 2 had serum sickness. In laboratory tests, rituximab bound the cryoglobulin and sped up its precipitation. Those with reactions had higher cryoglobulin and lower C4 levels. The authors advised caution, the 375 mg protocol, and plasma exchange first when cryoglobulin levels are high (Sène 2009). Details are on the main page.

Back to Table of Contents

Older Interferon-Based Cure for Comparison

Before direct-acting antivirals, interferon cured a minority of patients and caused many side effects.

• A meta-analysis of 10 studies and 300 patients found virologic response of 42% overall: 52% with peginterferon and 32% with conventional interferon. About 15% stopped or reduced treatment (Fabrizi 2013).
• In 72 Paris patients followed for a mean of 39.7 months, complete clinical response was 62.5%, virologic response 58.3% and cryoglobulin clearance 45.8%. There were 8 deaths (11.1%). An early virologic response predicted a complete clinical response (Saadoun 2006).
• A small series of 9 patients on peginterferon and ribavirin had 7 cured, all with a complete clinical response, and cryoglobulins cleared in 5 (Cacoub 2005).
• Adding telaprevir or boceprevir to peginterferon and ribavirin produced a complete clinical and virologic response in 66.7% of 30 severe or refractory patients. Serious adverse events occurred in 46.6%, and 46.6% needed red blood cell transfusion (Saadoun 2015).
• In a historical group at one health care network, peginterferon and ribavirin cured only 10%. All had side effects, and 50% stopped early (Sise 2016).

Cure by interferon did not rule out later trouble either. Relapse despite cure (Landau 2008), and persistent vasculitis in 4 patients (Levine 2005), were both described in the interferon era.

Lower Relapse After Interferon in Some Studies

Some direct comparisons favor interferon on what happens after cure. In Rome, response rates among those cured were similar for direct-acting antivirals (92%) and interferon (86%). Relapse, though, was 18% against 3%, and the direct-acting antiviral group reduced cryoglobulins and clones less efficiently. The authors state that interferon "may be superior" on these outcomes, possibly because it slows cell growth, while being "largely inferior" on an intention-to-treat basis (Colantuono 2021). A three-way comparison from Egypt found no significant difference in clinical response between regimens, no significant clinical and laboratory relapse on the interferon regimen, and more DNA damage in patient samples on the interferon-free regimens (Allam 2024).

These comparisons are small and retrospective or non-randomized. They also have a built-in limit: because interferon cured roughly half of patients or fewer, a group of people cured by interferon contains those who could finish it and respond to it, and those who could not are missing from it. The comparison therefore does not show what would happen if the same people received each treatment.

Back to Table of Contents

Follow-Up Measures the Studies Used

These are the things researchers measured. The papers read for this page did not test whether one follow-up schedule leads to better results than another. The monitoring described for lymphoma is covered on the main page.

• Virus: hepatitis C RNA in the blood, with cure counted at week 12 and often rechecked at week 24 (Gragnani 2016). Research studies also tested the cryoprecipitate and blood cells (Landau 2008).
• Symptoms: the Birmingham Vasculitis Activity Score (Bonacci 2017; Bonacci 2018). The Italian cohort graded purpura on a 4-point scale and scored nerve symptoms with a visual scale and, when possible, electromyography (Kondili 2022).
• Cryoglobulins and immune tests: cryocrit or cryoglobulin level, rheumatoid factor and complement C4 (Saadoun 2017; Kondili 2022).
• Kidney: serum creatinine and urine protein (Kondili 2022), and estimated filtering rate (Chang 2024).
• Nerves: nerve conduction tests, muscle strength scores, pain and disability questionnaires (Zanone 2021).
• B-cell clones: flow cytometry of blood cells, free light chain ratios, t(14;18) testing (Gragnani 2021), and antibody gene and MYD88 testing (Mazzaro 2023; Pozzato 2020).
• Autoantibodies: In one study, new autoantibodies appeared after cure in 5 patients, one with autoimmune hepatitis and one with primary sclerosing cholangitis (Lauletta 2024).

How Often Studies Tested

• Every 4 weeks to week 24, and again at week 36 (Saadoun 2017).
• Before treatment and at 12, 48 and 96 weeks after it (Lauletta 2024).
• Every 3 to 6 months for 12 years (Chang 2025).
• Yearly after cure (Elthes 2025).
• Whenever each centre's normal checkups took place (Kondili 2022).

Since relapse in the largest cohort rose mainly between 12 and 24 months (Fayed 2022), and median deterioration in the Italian cohort came at 19 months (Kondili 2022), short studies that stop at 12 or 24 weeks after treatment miss much of this period.

Back to Table of Contents

What Is Not Known

• The true relapse rate. Figures vary from none to 18%, partly because of different definitions, follow-up lengths and patient groups. The largest study is retrospective.
• Why relapse rises in the second year. The sharp increase between 12 and 24 months comes from one large cohort, and the papers read here offer no agreed explanation. The suggestion that dormant clones are reactivated remains a hypothesis (Visentini 2019).
• Who needs treatment beyond antivirals. The clonal markers and gene variants that track with persistence have not been tested in trials that use them to guide care (Gragnani 2021; Danishwar 2022).
• Rituximab after cure. No randomized trial in cured patients was found.
• Whether kidney scarring reverses. The papers read here measured creatinine, urine protein and filtering rate. None reported repeat biopsies showing that scarring had reversed.
• Nerve recovery. Results range from no improvement (Elthes 2025) to clear improvement (Zanone 2021), in groups that are not comparable.
• Lymphoma risk after cure in the direct-acting antiviral era. Reviews call for longer follow-up and larger studies (Cacoub 2022; Mazzaro 2026). The papers read here do not measure how many persistent clones become lymphoma.
• Liver cancer after cure with cryoglobulinemia. Findings point in different directions. In one Italian group, mixed cryoglobulinemia predicted liver cancer or death, with a hazard ratio of 3.46 (Colussi 2019). In a Taiwanese 12-year cohort, liver cancer appeared later in cured people with cryoglobulinemia, and the authors tied this to fewer regulatory B cells (Chang 2025).
• Direct comparison of treatments. The Cochrane review stated that studies with direct-acting antivirals are urgently needed. It included none, and a 2018 meta-analysis found no randomized comparison of cure against no cure for this question (Montero 2018; Cacoub 2018).

Back to Table of Contents

Key Research Papers

1. Abdelhamid WAR, Shendi A, Zahran M, Elbary EA, Fadda S. Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents. J Bras Nefrol. 2022;44(2):291-295. PubMed PMID: 33605311
2. Allam WR, Hegazy MT, Hussein MA, Zoheir N, Quartuccio L, El-Khamisy SF, et al. A comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis. Sci Rep. 2024;14(1):11840. PubMed PMID: 38782988
3. Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527-2532. PubMed PMID: 27605512
4. Bonacci M, Lens S, Londoño MC, Mariño Z, Cid MC, Ramos-Casals M, et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2017;15(4):575-583.e1. PubMed PMID: 27725289
5. Bonacci M, Lens S, Mariño Z, Londoño MC, Rodriguez-Tajes S, Sánchez-Tapias JM, et al. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology. 2018;155(2):311-315.e6. PubMed PMID: 29705529
6. Boonpheng B, Ungprasert P. Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. Cureus. 2026;18(2):e103349. PubMed PMID: 41835697
7. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005;52(3):911-5. PubMed PMID: 15751068
8. Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67(11):2025-2034. PubMed PMID: 29703790
9. Cacoub P, Si Ahmed SN, Ferfar Y, Pol S, Thabut D, Hezode C, et al. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol. 2019;17(3):518-526. PubMed PMID: 29857143
10. Cacoub P, Comarmond C, Vieira M, Régnier P, Saadoun D. HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol. 2022;76(1):174-185. PubMed PMID: 34600000
11. Chang ML, Cheng JS, Chen WT, Hsu CW, Chen KH, Chen YC, et al. Long-term renal function alterations in hepatitis C patients with SVRs: Impacts of therapies and mixed cryoglobulinemia. J Infect Public Health. 2024;17(3):486-494. PubMed PMID: 38280352
12. Chang ML, Cheng JS, Chen WT, Shen YJ, Kuo CJ, Chien RN. Mixed cryoglobulinemia decelerates hepatocellular carcinoma development in hepatitis C patients with SVR by downregulating regulatory B cells: a 12-year prospective cohort study. Oncoimmunology. 2025;14(1):2470128. PubMed PMID: 40008547
13. Chowdhury R, Tsen A. Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report. Am J Kidney Dis. 2017;70(2):301-304. PubMed PMID: 28343737
14. Colantuono S, Mitrevski M, Yang B, Tola J, Carlesimo M, De Sanctis GM, et al. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis. Clin Rheumatol. 2017;36(3):617-623. PubMed PMID: 28111716
15. Colantuono S, Marrapodi R, Del Padre M, Collalti G, Garzi G, De Santis A, et al. Clinico-immunological outcomes of HCV-cured cryoglobulinemia: Lower relapse rate with interferon-based than interferon-free therapy. Liver Int. 2021;41(1):70-75. PubMed PMID: 33064930
16. Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, et al. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World J Gastroenterol. 2019;25(40):6094-6106. PubMed PMID: 31686765
17. Comarmond C, Garrido M, Pol S, Desbois AC, Costopoulos M, Le Garff-Tavernier M, et al. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Gastroenterology. 2017;152(8):2052-2062.e2. PubMed PMID: 28274850
18. Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127(4):413-7. PubMed PMID: 25746436
19. Covic A, Caruntu ID, Burlacu A, Giusca SE, Covic A, Stefan AE, et al. Therapeutic Potential of Rituximab in Managing Hepatitis C-Associated Cryoglobulinemic Vasculitis: A Systematic Review. J Clin Med. 2023;12(21):6806. PubMed PMID: 37959271
20. Danishwar M, Jamil Z, Khan S, Nakhla M, Ahmad I, Ali MA, et al. Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure. J Clin Med. 2022;11(4):984. PubMed PMID: 35207257
21. Dashjamts G, Ganzorig AE, Tsedendorj Y, Dondov G, Nergui O, Badamjav T, et al. Post-Treatment Occurrence of Serum Cryoglobulinemia in Chronic Hepatitis C Patients. Diagnostics (Basel). 2024;14(11):1188. PubMed PMID: 38893714
22. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843-53. PubMed PMID: 22147661
23. Elthes BZ, Vitalis Z, Papp M, Tornai T, Tornai D, Tornai I. Long Term Follow-Up of Patients with Cryoglobulinemia After Successful Treatment of Chronic C Virus Hepatitis. Dig Dis Sci. 2025;70(7):2467-2474. PubMed PMID: 40210820
24. Emery JS, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H, et al. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Am J Gastroenterol. 2017;112(8):1298-1308. PubMed PMID: 28291241
25. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol. 2013;85(6):1019-27. PubMed PMID: 23588727
26. Fabrizi F, Cerutti R, Porata G, Messa P, Ridruejo E. Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. Pathogens. 2019;8(4):176. PubMed PMID: 31590268
27. Fabrizi F, Donato MF, Alfieri CM, Podestà MA, Nardelli L, Castellano G. Novel evidence on the management of HCV-associated glomerular disease. Nefrologia (Engl Ed). 2025;45(9):501349. PubMed PMID: 41276383
28. Fayed A, El Nokeety MM, Samy Abdelaziz T, Samir HH, Hamza WM, El Shabony T. Incidence and Characteristics of de novo Renal Cryoglobulinemia After Direct-Acting Antivirals Treatment in an Egyptian Hepatitis C Cohort. Nephron. 2018;140(4):275-281. PubMed PMID: 30359992
29. Fayed A, Hegazy MT, Biard L, Vieira M, El Shabony T, Saadoun D, et al. Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. Am J Gastroenterol. 2022;117(4):627-636. PubMed PMID: 35103020
30. Galli M, Monti G, Marson P, Scaini P, Pietrogrande M, Candela M, et al. Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev. 2019;18(8):778-785. PubMed PMID: 31181326
31. Gaudêncio M, Nogueira R, Afonso N. Mixed Cryoglobulinaemia Vasculitis after Persistent Hepatitis C Virus Eradication. Eur J Case Rep Intern Med. 2021;8(8):002808. PubMed PMID: 34527630
32. Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473-1482. PubMed PMID: 27483451
33. Gragnani L, Lorini S, Marri S, Basile U, Santarlasci V, Monti M, et al. Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. Hepatology. 2021;74(3):1164-1173. PubMed PMID: 33721342
34. Hassan AM, Osman HA, Mahmoud HS, Hassan MH, Hashim AA, Ameen HH. Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience. Infect Drug Resist. 2018;11:895-901. PubMed PMID: 29983581
35. Ishitoku M, Yoshida Y, Matsubara T, Fujii K, Yorishima A, Oka N, et al. Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C. Intern Med. 2023;62(13):1999-2004. PubMed PMID: 36384905
36. Kondili LA, Monti M, Quaranta MG, Gragnani L, Panetta V, Brancaccio G, et al. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology. 2022;76(1):220-232. PubMed PMID: 34919289
37. Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604-11. PubMed PMID: 18240235
38. Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther. 2017;19(1):74. PubMed PMID: 28388935
39. Lauletta G, Cicco S, Dammacco F. Hepatitis C virus-related autoimmunity before and after viral clearance: a single center, prospective, observational study. Minerva Med. 2024;115(3):284-292. PubMed PMID: 38695632
40. Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol. 2005;32(6):1164-7. PubMed PMID: 15940780
41. Martin P, Awan AA, Berenguer MC, Bruchfeld A, Fabrizi F, Goldberg DS, et al. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. 2022;102(6):1228-1237. PubMed PMID: 36411019
42. Mazzaro C, Dal Maso L, Quartuccio L, Ghersetti M, Lenzi M, Mauro E, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;36 Suppl 111(2):107-114. PubMed PMID: 29465371
43. Mazzaro C, Visentini M, Gragnani L, Vit F, Tissino E, Pozzo F, et al. Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders. Br J Haematol. 2023;203(2):237-243. PubMed PMID: 37491625
44. Mazzaro C, Bomben R, Gragnani L, Visentini M, Agostinis P, Marri S, et al. The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders. Cancers (Basel). 2026;18(15):2501. PubMed PMID: 42588717
45. Montero N, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, et al. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev. 2018;5(5):CD011403. PubMed PMID: 29734473
46. Pelletier K, Royal V, Mongeau F, Meunier RS, Dion D, Jao K, et al. Persistent Mixed Cryoglobulinemia Despite Successful Treatment of Hepatitis C, Aggressive B-Cell-Directed Therapies, and Long-term Plasma Exchanges. Kidney Int Rep. 2019;4(8):1194-1198. PubMed PMID: 31440712
47. Pozzato G, Mazzaro C, Artemova M, Abdurakhmanov D, Grassi G, Crosato I, et al. Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses. Br J Haematol. 2020;191(5):775-783. PubMed PMID: 32790920
48. Pérez de José A, Carbayo J, Pocurull A, Bada-Bosch T, Cases Corona CM, Shabaka A, et al. Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study. Clin Kidney J. 2021;14(2):586-592. PubMed PMID: 33623683
49. Quartuccio L, Bortoluzzi A, Scirè CA, Marangoni A, Del Frate G, Treppo E, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clin Rheumatol. 2023;42(2):359-370. PubMed PMID: 36169798
50. Rutledge SM, Chung RT, Sise ME. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial Int. 2018;22 Suppl 1:S81-S96. PubMed PMID: 29694729
51. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696-706. PubMed PMID: 17075881
52. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-34; quiz 504-5. PubMed PMID: 20439619
53. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol. 2015;62(1):24-30. PubMed PMID: 25135864
54. Saadoun D, Thibault V, Si Ahmed SN, Alric L, Mallet M, Guillaud C, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777-82. PubMed PMID: 26567178
55. Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, et al. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. Gastroenterology. 2017;153(1):49-52.e5. PubMed PMID: 28288791
56. Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408-17. PubMed PMID: 26474537
57. Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60(12):3848-55. PubMed PMID: 19950292
58. Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889-96. PubMed PMID: 26031898
59. Visentini M, Del Padre M, Colantuono S, Yang B, Minafò YA, Antonini S, et al. Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. Liver Int. 2019;39(4):628-632. PubMed PMID: 30690862
60. Zanone MM, Marinucci C, Ciancio A, Cocito D, Zardo F, Spagone E, et al. Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study. Liver Int. 2021;41(11):2611-2621. PubMed PMID: 34219359

PubMed Topic Searches

1. PubMed: cryoglobulinemic vasculitis relapse after sustained virologic response
2. PubMed: cryoglobulinemia, direct-acting antivirals and B-cell clones
3. PubMed: cryoglobulinemic glomerulonephritis and direct-acting antivirals
4. PubMed: rituximab in hepatitis C cryoglobulinemia

Back to Table of Contents

Connections

• Cryoglobulinemia — the main page on this disease
• Hepatitis C
• Hepatitis Panel
• Vasculitis
• Lymphoma
• Glomerulonephritis
• Peripheral Neuropathy
• Rheumatoid Factor Test
• Complement Test

Featured Videos